Alun John Smith

Title: Alun John Smith: Innovator in Therapeutic Compounds

Introduction

Alun John Smith is a notable inventor based in Nottingham, GB. He has made significant contributions to the field of therapeutic compounds, holding a total of five patents. His work primarily focuses on enzyme inhibitors and their applications in treating various diseases.

Latest Patents

Among his latest patents, one invention provides compounds that serve as enzyme inhibitors. This invention includes compositions comprising such compounds and their use in therapy, particularly for conditions where plasma kallikrein activity is implicated. Another patent involves 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives. This invention relates to the use of these compounds as phosphoinositide 3-kinase inhibitors, especially in the treatment of inflammatory diseases, including respiratory inflammatory diseases.

Career Highlights

Throughout his career, Alun John Smith has worked with various companies, including Respivert Limited and Kalvista Pharmaceuticals Limited. His innovative work has contributed to advancements in therapeutic treatments and has positioned him as a key figure in his field.

Collaborations

Alun has collaborated with notable individuals such as David Michel, Adrien Taddei, and Stuart Thomas Onions. These collaborations have further enhanced his research and development efforts in the pharmaceutical industry.

Conclusion

Alun John Smith's contributions to the field of therapeutic compounds through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the treatment of diseases, showcasing the importance of innovation in healthcare.